Guess Who Picked Up Texas Roadhouse Inc. (NASDAQ:TXRH) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Texas Roadhouse Inc. (NASDAQ:TXRH) reported that Taylor Wayne Kent has picked up 4,108,231 of common stock as of 2017-02-28.
The acquisition brings the aggregate amount owned by Taylor Wayne Kent to a total of 4,108,231 representing a 5.8% stake in the company.
For those not familiar with the company, Texas Roadhouse, Inc. is a restaurant company, which operates in the casual dining segment. The Company offers an assortment of seasoned and aged steaks hand-cut daily on the premises and cooked to order over open grills. In addition to steaks, the Company also offers its guests a selection of ribs, fish, seafood, chicken, pork chops, pulled pork and vegetable plates, and an assortment of hamburgers, salads and sandwiches. The Company’s entrees include over two made-from-scratch side items and it offers all its guests a free unlimited supply of roasted in-shell peanuts and fresh baked yeast rolls. The Company owns approximately 400 company restaurants and over 80 franchise restaurants in approximately 50 states and over four foreign countries. Of the over 400 restaurants the Company operates approximately 392 as Texas Roadhouse and operates over seven as Bubba’s 33 restaurants. In addition, the Company operates over two restaurants outside of the casual dining segment.
A glance at Texas Roadhouse Inc. (NASDAQ:TXRH)’s key stats reveals a current market capitalization of 2.97 billion based on 70.62 million shares outstanding and a price at last close of $42.30 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-08-03, Zarley picked up 23,800 at a purchase price of $42.23. This brings their total holding to 23,800 as of the date of the filing.
On the sell side, the most recent transaction saw Colosi unload 12,377 shares at a sale price of $48.21. This brings their total holding to 70,058.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Texas Roadhouse Inc. (NASDAQ:TXRH) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Fiesta Restaurant Group Inc. (NASDAQ:FRGI) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Fiesta Restaurant Group Inc. (NASDAQ:FRGI) reported that Jcp Investment Management, Llc. has picked up 455,012 of common stock as of 2017-02-28.
The acquisition brings the aggregate amount owned by Jcp Investment Management, Llc. to a total of 455,012 representing a 1.69% stake in the company.
For those not familiar with the company, Fiesta Restaurant Group, Inc. (Fiesta) owns, operates and franchises approximately two fast-casual restaurant brands, Pollo Tropical and Taco Cabana. The Company operates through the Pollo Tropical and Taco Cabana segments. Its Pollo Tropical is a fast-casual restaurant brand offering a range of Caribbean food. Taco Cabana restaurants offers a selection of hand-made Mexican food. Pollo Tropical restaurants offer Caribbean menu items, featuring its bone-in chicken marinated in blend of tropical fruit juices and grilled over an open flame. Its Taco Cabana restaurants serves Mexican food, including flame-grilled steak and chicken fajitas served on sizzling iron skillets, quesadillas, hand-rolled flautas, enchiladas, burritos, tacos flour tortillas, customizable salads served in its Cabana Bowl, and its breakfast tacos. It also offer a self-serve salsa bar, which includes a selection of made-from-scratch salsas, sauces, sliced jalapenos, chopped cilantro, chopped onions and other items.
A glance at Fiesta Restaurant Group Inc. (NASDAQ:FRGI)’s key stats reveals a current market capitalization of 526.28 million based on 26.76 million shares outstanding and a price at last close of $19.85 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-05-1, Meisenheimer picked up 2,600 at a purchase price of $26.32. This brings their total holding to 26,814 as of the date of the filing.
On the sell side, the most recent transaction saw Todd unload 32 shares at a sale price of $23.45. This brings their total holding to 14,054.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Fiesta Restaurant Group Inc. (NASDAQ:FRGI) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Amyris Inc. (NASDAQ:AMRS) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Amyris Inc. (NASDAQ:AMRS) reported that Temasek Holdings (private) Ltd. has picked up 61,764,891 of common stock as of 2017-02-27.
The acquisition brings the aggregate amount owned by Temasek Holdings (private) Ltd. to a total of 61,764,891 representing a 22.1% stake in the company.
For those not familiar with the company, Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.
A glance at Amyris Inc. (NASDAQ:AMRS)’s key stats reveals a current market capitalization of 140.76 million based on 273.83 Million shares outstanding and a price at last close of $0.523 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-06-14, Doerr picked up 200,577 at a purchase price of $1.04. This brings their total holding to 13,037,586 as of the date of the filing.
On the sell side, the most recent transaction saw Maxwell unload 254,570 shares at a sale price of $0.54. This brings their total holding to 56,812,277.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Amyris Inc. (NASDAQ:AMRS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Biotechnology Value Fund is Buying Xoma Corp (NASDAQ:XOMA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Xoma Corp (NASDAQ:XOMA) reported that Biotechnology Value Fund L P has picked up 695,726 of common stock as of 2017-02-21.
The acquisition brings the aggregate amount owned by Biotechnology Value Fund L P to a total of 695,726 representing a 9.2% stake in the company.
For those not familiar with the company, XOMA Corporation (NASDAQ:XOMA) is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.
A glance at Xoma Corp (NASDAQ:XOMA)’s key stats reveals a current market capitalization of 39.56 million based on 7.52 million shares outstanding and a price at last close of $5.16 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2013-08-19, Baker picked up 21,410 at a purchase price of $3.62. This brings their total holding to 510,449 as of the date of the filing.
On the sell side, the most recent transaction saw Neal unload 95 shares at a sale price of $4.50. This brings their total holding to 20,471.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Xoma Corp (NASDAQ:XOMA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Calithera Biosciences Inc. (NASDAQ:CALA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Calithera Biosciences Inc. (NASDAQ:CALA) reported that Viking Global has picked up 1,607,936 of common stock as of 2017-02-21.
The acquisition brings the aggregate amount owned by Viking Global to a total of 1,607,936 representing a 7.8% stake in the company.
For those not familiar with the company, Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.
A glance at Calithera Biosciences Inc. (NASDAQ:CALA)’s key stats reveals a current market capitalization of 201.87 million based on 21.82 million shares outstanding and a price at last close of $9.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-16, Adage picked up 500,000 at a purchase price of $3.15. This brings their total holding to 3,635,069 as of the date of the filing.
On the sell side, the most recent transaction saw Hecht unload 970 shares at a sale price of $6.58. This brings their total holding to 8,625.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Calithera Biosciences Inc. (NASDAQ:CALA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) reported that Great Point Partners has picked up 2,216,216 of common stock as of 2017-02-17.
The acquisition brings the aggregate amount owned by Great Point Partners to a total of 2,216,216 representing a 5.04% stake in the company.
For those not familiar with the company, Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.
A glance at Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s key stats reveals a current market capitalization of 659.20 million based on 43.93 million shares outstanding and a price at last close of $15.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-16, Flynn picked up 3,239 at a purchase price of $8.97. This brings their total holding to 1,103,617 as of the date of the filing.
On the sell side, the most recent transaction saw Baroldi unload 16,300 shares at a sale price of $15.51. This brings their total holding to 54,365.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Genvec Inc. (NASDAQ:GNVC) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Genvec Inc. (NASDAQ:GNVC) reported that Mmcap International Inc. Spc has picked up 114,827 of common stock as of 2017-02-16.
The acquisition brings the aggregate amount owned by Mmcap International Inc. Spc to a total of 114,827 representing a 5.05% stake in the company.
For those not familiar with the company, GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
A glance at Genvec Inc. (NASDAQ:GNVC)’s key stats reveals a current market capitalization of 16.66 million based on 2.27 million shares outstanding and a price at last close of $7.15 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-09-16, Swirsky picked up 10,000 at a purchase price of $0.50. This brings their total holding to 252,500 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Genvec Inc. (NASDAQ:GNVC) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sawyer Philip M. Picked Up Invuity Inc. (NASDAQ:IVTY) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Invuity Inc. (NASDAQ:IVTY) reported that Sawyer Philip M. has picked up 788,444 of common stock as of 2017-02-14.
The acquisition brings the aggregate amount owned by Sawyer Philip M. to a total of 788,444 representing a 4.5% stake in the company.
For those not familiar with the company, Invuity is a medical technology company focused on pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during open minimally invasive and minimal access procedures. The patented Intelligent Photonics technology enables superior illumination and visualization and is designed to overcome the significant limitations of traditional surgical lighting options in the operating room. Our patented Intelligent Photonics is integrated into our single-use and reusable advanced surgical devices to address some of the critical intracavity illumination and visualization challenges facing surgeons today. These devices utilize our proprietary optical waveguide technology to direct and shape thermally cool, brilliant light into broad, uniform and volumetric illumination of the surgical target.
A glance at Invuity Inc. (NASDAQ:IVTY)’s key stats reveals a current market capitalization of 116.82 million based on 16.93 million shares outstanding and a price at last close of $6.95 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-08, Mackaness picked up 1,700 at a purchase price of $5.75. This brings their total holding to 3,700 as of the date of the filing.
On the sell side, the most recent transaction saw Flynn unload 45,568 shares at a sale price of $6.01. This brings their total holding to 1,690,498.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Invuity Inc. (NASDAQ:IVTY) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.